School of Medicine, Nankai University, Tianjin, China.
Department of Cardiology Tianjin Chest Hospital, Tianjin, China.
J Int Med Res. 2020 Jun;48(6):300060520926349. doi: 10.1177/0300060520926349.
Statins have been shown to be beneficial for the prevention of cardiovascular events. In elderly individuals, the efficacy of statins remains controversial and the comparative effect of statins has not been assessed.
MEDLINE, Embase, and the Cochrane Central database were searched for randomized controlled trials that assessed statins in older patients.
Seventeen trials were analyzed. When used for secondary prevention, statins were associated with reduced risk of cardiovascular events, all-cause mortality, cardiovascular mortality, revascularization, and stroke. When used for primary prevention, statins reduced the risk of myocardial infarction and revascularization, but did not significantly affect other outcomes. A modest difference between pharmaceutical statin products was found, and high-quality evidence indicated that intensive atorvastatin had the greatest benefits for secondary prevention.
In secondary prevention, evidence strongly suggests that statins are associated with a reduction in the risk of all-cause mortality, cardiovascular events, cardiovascular mortality, and revascularization. However, differences in the effects of various statins do not appear to have significant effects on therapy in secondary prevention for the elderly.
他汀类药物已被证明对预防心血管事件有益。在老年人中,他汀类药物的疗效仍存在争议,且尚未评估他汀类药物的比较效果。
检索 MEDLINE、Embase 和 Cochrane 中央数据库中评估老年患者使用他汀类药物的随机对照试验。
分析了 17 项试验。在二级预防中,他汀类药物与降低心血管事件、全因死亡率、心血管死亡率、血运重建和卒中风险相关。在一级预防中,他汀类药物降低了心肌梗死和血运重建的风险,但对其他结局没有显著影响。发现不同药物他汀类产品之间存在适度差异,高质量证据表明,强化阿托伐他汀对二级预防的获益最大。
在二级预防中,证据强烈表明他汀类药物与降低全因死亡率、心血管事件、心血管死亡率和血运重建风险相关。然而,各种他汀类药物的效果差异似乎对老年患者的二级预防治疗没有显著影响。